Group 1 - The primary goal of the "High Income DIY Portfolios" service is to provide high income with low risk and capital preservation for DIY investors [1] - The service offers six different portfolios tailored for various income-seeking investors, including retirees or near-retirees [1] - The portfolios include two High-Income portfolios, a Dividend Growth Investing (DGI) portfolio, a conservative strategy for 401K accounts, a Sector-Rotation strategy, and a High-Growth portfolio [1] Group 2 - The "High Income DIY Portfolios" service includes a total of 10 model portfolios with varying income targets and risk levels, along with buy and sell alerts and live chat support [2] - The investment approach focuses on dividend-growing stocks with a long-term horizon, aiming for lower drawdowns and sustainable yields [2] - The service is designed to help investors create stable, long-term passive income [2]

US FDA flags seizure risk with certain Parkinson's drugs, seeks label warnings | Reuters Skip to main content Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv Follow Amneal Pharmaceuticals Inc Follow Novartis AG Follow Show more companies March 20 (Reuters) - The U.S. Food and Drug Administration said on Friday it has notified manufacturers of certain Parkinson's disease treatments to update their prescribing information with a new warning about a potential risk ...

美容护理 2026 年 03 月 20 日 行 业 研 究 / 行 业 深 度 相关研究 证 券 研 究 报 告 联系人 证券分析师 行 业 及 产 业 王立平 A0230511040052 wanglp@swsresearch.com 聂霜 A0230524120002 nieshuang@swsresearch.com 聂霜 A0230524120002 nieshuang@swsresearch.com 全球业绩陆续企稳，中国市场曙光现 看好 ——国际化妆品医美公司 25 年业绩跟踪报告 本期投资提示： 请务必仔细阅读正文之后的各项信息披露与声明 本研究报告仅通过邮件提供给 中庚基金 使用。1 投资案件 - ⚫ 2025 年全球美妆市场持续低速增长，受此影响，各大国际集团 2025 年收入端表现略 疲软，但整体开始企稳。据欧莱雅集团数据，2025 年全球美妆市场增速 3.5%，相比 24 年 4.5%的增长，以及 23 年 8%的高增长，需求端增速持续回落。需求端的疲软表 现，继续考验各国际集团的战略与适应能力，逆境行舟不进则退。20-24 年由于疫情、 宏观经济因素、中国市场疲软等多方面因素影响，各大 ...

AbbVie Inc. (NYSE:ABBV) is included among the 15 Dividend Stocks to Buy for Steady Income. AbbVie, Alloy Therapeutics Ink Deal to Develop Next-Gen Antibody Platform On March 17, Alloy Therapeutics announced an agreement with AbbVie Inc. (NYSE:ABBV) to develop a new antibody platform. The goal is to discover potent and specific antibodies for targets that current technologies struggle to address. Under the multi-year deal, Alloy will receive an upfront payment, along with an additional payment tied to del ...

Key Takeaways AbbVie shares dropped 5.2% as J&J secured FDA approval for Icotyde in plaque psoriasis.Skyrizi, AbbVie's top drug, posted $17.6B sales in 2025 and is key to post-Humira growth.Icotyde's oral delivery and expanding indications may intensify IL-23 competition over time.Shares of AbbVie (ABBV) fell 5.2% on Wednesday, wiping out more than $20 billion in market value. This selloff comes as investors grow wary of Johnson & Johnson’s (JNJ) newly approved immunology therapy, Icotyde, which could emerg ...

Core Insights - Allergan Aesthetics has conducted a global survey involving over 12,000 consumers, revealing a shift towards multimodal treatment plans and a preference for holistic, natural results in aesthetic treatments [1][2][13] - The findings will be presented at the Aesthetic and Anti-Aging Medicine World Congress (AMWC) 2026 in Monaco, showcasing the evolution of the AA Signature™ framework to meet changing patient expectations [1][3] Group 1: Evolving Patient Expectations - Patients are increasingly open to exploring treatment combinations and desire personalized, long-term aesthetic plans, with 62% finding multiple aesthetic treatments appealing and 59% likely to adopt a structured multi-treatment approach [3][5] - A significant 78% of consumers expressed that they would feel more satisfied with their aesthetic journey if they worked towards an agreed long-term plan with their practitioner [3] Group 2: New Educational Solutions - Allergan Aesthetics will introduce a new report titled "Layered Beauty: The New Aesthetic Mindset" at AMWC 2026, which emphasizes the importance of structured treatment frameworks and education for practitioners [3][10] - The AA Signature™ Skin360+ initiative is designed to address real-world consumer needs by integrating injectable treatments with energy-based devices, reflecting the company's commitment to evolving its portfolio [5][6] Group 3: Scientific Innovation and Events - The AMWC 2026 will feature live injection sessions and symposia focusing on multimodal approaches in aesthetic practice, highlighting the integration of science and education in delivering personalized outcomes [7][8][10] - Allergan Aesthetics will present 21 scientific e-posters that showcase its leadership in advancing multimodal approaches to aesthetics, reinforcing its commitment to innovation [8][10]

TrumpRx lists many medicines at prices higher than paid in UK | Reuters Skip to main content Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv U.S. dollar banknotes and medicines are seen in this illustration taken, June 27, 2024. REUTERS/Dado Ruvic/Illustration/File Photo Purchase Licensing Rights, opens new tab March 18 (Reuters) - U.S. President Donald Trumppledged to make prescription drugs cheaper for Americans than anywhere in the world, but his TrumpRx.gov ...

AbbVie Inc. (NYSE:ABBV) is one of Billionaire Ken Fisher’s 15 Most Notable Moves for 2026. AbbVie Inc. (NYSE:ABBV) is a constant part of the 13F portfolio of Fisher Asset Management since the start of 2013. Even though the fund trimmed this stake substantially around 2020, it has started buying shares of the company again since early 2025. In the last quarter of 2025, the fund upped the stake in AbbVie by 128% compared to third quarter filings. The holding now comprises close to 630,000 shares. In 2021, j ...

In a 3-0 decision, the 9th U.S. Circuit Court of Appeals in Pasadena, California said AbbVie (ABBV.N), opens new tab, AstraZeneca (AZN.L), opens new tab, Novartis (NOVN.S), opens new taband Sanofi (SASY.PA), opens new tabmust defend against claims they violated the federal False Claims Act through their involvement in the Section 340B Drug Pricing Program. Big drugmakers must face US overcharge claims on medications for low-income patients | Reuters Skip to main content Exclusive news, data and analytics fo ...

Key Takeaways AbbVie fell below its 50-day SMA, hinting at short-term weakness, but remains above 200-day trendSkyrizi and Rinvoq drove growth with $26B sales in 2025, expected to exceed $31B in 2026Humira erosion and weak aesthetics sales persist, but pipeline, M&A, and new drugs support growthAbbVie (ABBV) stock slipped below its 50-day simple moving average (SMA) on March 13, after consistently trading above it since mid-Feb. However, the stock has remained comfortably above its 200-day SMA for more than ...